MAPT and Alzheimer disease: CSF p-tau levels were significantly higher in AD patients (87, IQR 72–117; n = 85) than in CJD (49, IQR 36–67; n = 294) and the other non-CJD patients (48.5, IQR 30.8–75; n = 226) (AD vs. CJD p < 0.001; other non-CJD vs. CJD p = 0.744; AD vs. other non-CJD p < 0.001).